Association between Sleep Duration and Urinary Albumin Excretion in Patients with Type 2 Diabetes: The Fukuoka Diabetes Registry

Objective

Few studies have so far investigated the impact of sleep duration on chronic kidney disease in diabetic patients. The objective of the present study was to examine the relationship between sleep duration and albuminuria in type 2 diabetic patients.

Research Design and Methods

A total of 4,870 Japanese type 2 diabetic patients ≥20 years of age were divided into six groups according to self-reported sleep duration: less than 4.5 hours, 4.5–5.4 hours, 5.5–6.4 hours, 6.5–7.4 hours, 7.5–8.4 hours and more than 8.5 hours. The association between sleep duration and urinary albumin-creatinine ratio (UACR) was examined cross-sectionally.

Results

Both short and long sleep durations were significantly associated with higher UACR levels and higher proportions of patients with albuminuria (≥30 mg/g) and macroalbuminuria (≥300 mg/g) compared with a sleep duration of 6.5–7.4 hours (P for quadratic trend <0.001). A U-shaped association between sleep duration and UACR remained significant even after adjustment for potential confounders, including age, sex, duration of diabetes, current smoking habits, former smoking habits, current drinking habits, regular exercise habits, total energy intake, total protein intake, hypnotic use and estimated glomerular filtration rate. Furthermore, the association remained substantially unchanged after additional adjustment for body mass index, hemoglobin A_1c, systolic blood pressure, renin-angiotensin system inhibitor use and depressive symptoms.

Conclusions

Our findings suggest that sleep duration has a U-shaped association with the UACR levels in type 2 diabetic patients, independent of potential confounders.     

Relationship between Serum Nickel and Homocysteine Concentration in Hemodialysis Patients

Severe hyperhomocysteinemia (HHC) is associated with atherosclerosis. In hemodialysis (HD) patients, one of the main causes of death is cardiovascular disease. In animals, trace elements such as cobalt, copper, iron, and nickel ameliorated vitamin B(12) deficiency-induced HHC. However, correlations between plasma total homocysteine (tHcy) and trace elements in HD patients have not been investigated. Therefore, tHcy, folate, vitamin B(12), trace elements (cobalt, copper, iron, and nickel), and some laboratory parameters such as serum total protein, albumin, transferrin, ferritin, C-reactive protein (CRP), and interleukin-6 concentrations were determined in 122 hemodialysis patients. When patients were divided into groups according to their tHcy, we found no significant differences in concentrations of cobalt, copper, and total protein, while nickel was higher, and folate, vitamin B(12), and iron were lower in patients with lower than higher tHcy. In univariate regression analysis, tHcy negatively correlated with concentrations of folate (r = -0.302, p < 0.006), vitamin B(12) (r = -0.347, p < 0.0001), nickel (r = -0.289, p < 0.006), and CRP (r = -0.230, p < 0.02) and positively with serum albumin (r = 0.316, p < 0.0004) and hemoglobin (r = 0.329, p < 0.0001) values. No relationship between tHcy and serum concentrations of cobalt, copper, iron, or other laboratory parameters was found in HD patients. The effect of cobalt and nickel on homocysteine production was assessed in human peripheral mononuclear cells (PBMCs). Nickel but not cobalt at concentrations found in HD patients significantly inhibited homocysteine, cysteine, and S-adenosylhomocysteine production in human PBMCs. These results suggest that nickel might also be involved in the regulation of the methionine-folate cycle in humans, as was demonstrated in animal experiments.     

Serum Oxidized Albumin and Cardiovascular Mortality in Normoalbuminemic Hemodialysis Patients: A Cohort Study

Background

Substantial evidence suggests that increased oxidative stress in hemodialysis (HD) patients may contribute to cardiovascular complications. Oxidative modifications of human serum albumin (HSA), the largest thiol pool in plasma, alter its biological properties and may affect its antioxidant potential in HD patients.

Methods

We conducted a long-term follow-up study in a cohort of normoalbuminemic HD patients to examine the impact of redox state of serum albumin on patients’ survival by measuring the human nonmercaptoalbumin (HNA) fraction of HSA.

Results

After adjusting for potential demographic, anthropometric, and clinical confounders, a positive association of HNA level with the risk of death from cardiovascular disease (CVD) and all-cause mortality was observed in normoalbuminemic HD patients. Using stratified analysis, we found a stronger association between HNA level and the risk of death from CVD and all-cause mortality in patients with pre-existing CVD.

Conclusions

Serum HNA level is a positive predictor of mortality in normoalbuminemic HD patients, especially among those with pre-existing CVD. Increased oxidative stress resulting from biological changes in serum albumin levels could contribute to accelerated atherosclerosis and the development of cardiovascular disease in HD patients.     

Diabetes Duration and the Efficacy and Safety of Insulin Glargine Versus Comparator Treatment in Patients with Type 2 Diabetes Mellitus

ObjectiveTo evaluate the effect of diabetes duration on efficacy and safety in patients with type 2 diabetes mellitus (T2DM) using insulin glargine versus comparator (oral antidiabetic drugs [OADs], dietary changes, or other insulins).MethodsData were pooled from randomized controlled clinical trials conducted in adults with T2DM with at least 24-week treatment with insulin glargine or a comparator, where predefined insulin titration algorithms were utilized to achieve fasting plasma glucose (FPG) concentrations of ≤ 100 mg/dL. Glycated hemoglobin A1C (A1C), FPG, and insulin dose and safety (hypoglycemia) outcomes were analyzed.ResultsNine studies were included in the analysis of 2,930 patients. Patients with shorter duration of diabetes were more likely to have greater reductions in A1C compared with those who had longer-duration disease (P < .0001). Disease duration did not affect change in FPG concentrations (P = .9017), but lower weight-adjusted insulin dose was correlated with longer-duration disease (P < .0001). Patients with longer-duration diabetes had increased risks of symptomatic hypoglycemia, confirmed hypoglycemia (self-monitored blood glucose < 50 mg/dL and < 70 mg/dL), and nocturnal hypoglycemia (all P < .001). No significant relationship was found between severe hypoglycemia and duration of diabetes. However, treatment with insulin glargine lowered A1C values more effectively than comparator treatments with fewer hypoglycemic episodes.ConclusionPatients with shorter-duration T2DM better achieved target A1C levels and had less hypoglycemia than those with longer disease duration. Insulin glargine was associated with reduced A1C and fewer hypoglycemic events than comparators, regardless of disease duration. (Endocr Pract. 2014;20:120-128)     

Diabetes Mellitus in Patients with Benign Prostatic Hyperplasia

Of 51 patients submitted to operation for benign prostatic hyperplasia three (5.9%) were knwon, diabetics and two others had undergone surgery for peptic ulcer. Of the remaining patients half (23 out of 46) were found to be diabetic; 40% (20 patients) had a history of previous cardiac infarction or electrocardiograph evidence of myocardial ischaemia.It is suggested that these findings add further support to the hypothesis that benign prostatic hyperplasia is one manifestation of a relative increase of oestrogen secretion with advancing age.     

血清Ferritin、Cat S、MCP-1与妊娠期糖尿病患者胰岛素抵抗的关系及妊娠结局的影响因素分析

摘要 目的：探讨血清铁蛋白（Ferritin）、组织蛋白酶S（Cat S）、单核细胞趋化蛋白-1（MCP-1）与妊娠期糖尿病（GDM）患者胰岛素抵抗的关系,并分析影响GDM患者妊娠结局的影响因素。方法：选取2019年4月～2021年12月期间来石家庄市妇幼保健院产检并诊断为GDM的产妇154例纳为GDM组,另取同期来石家庄市妇幼保健院产检的健康产妇100例作为对照组。检测对比两组的血清Ferritin、Cat S、MCP-1水平以及稳态模型胰岛素抵抗指数（HOMA-IR）,血清Cat S、Ferritin、MCP-1与HOMA-IR的相关性以Pearson相关系数进行分析。GDM组患者根据妊娠结局分为正常妊娠结局组和不良妊娠结局组,妊娠结局的影响因素采用多因素Logistic回归分析。结果：GDM组血清Ferritin、Cat S、MCP-1水平及HOMA-IR均高于对照组（P<0.05）。Pearson相关性分析结果显示,GDM患者的血清Cat S、Ferritin、MCP-1水平与HOMA-IR均呈正相关（P<0.05）。154例GDM患者中,有58例出现不良妊娠结局,占比37.66%。单因素分析结果显示,GDM患者的妊娠结局与糖尿病家族史、GDM确诊时孕周、年龄、口服葡萄糖耐量试验（OGTT）结果、孕前体质量指数（BMI）、血清Ferritin、Cat S、MCP-1水平以及HOMA-IR有关（P<0.05）。多因素Logistic回归分析结果显示：年龄≥35岁、孕前BMI≥24 kg/m²、OGTT结果＞2项异常、血清Ferritin、Cat S、MCP-1水平偏高是GDM患者妊娠结局不良的危险因素（P<0.05）。结论：GDM患者的血清Ferritin、Cat S、MCP-1水平异常升高,且与胰岛素抵抗有关。GDM患者的妊娠结局受到血清Ferritin、Cat S、MCP-1水平、年龄、孕前BMI、OGTT结果等因素影响。     

Influence of Therapy with Metformin on the Concentration of Certain Divalent Cations in Patients with Non-insulin-Dependent Diabetes Mellitus

Research was performed on a group of 30 patients with non-insulin-dependent diabetes mellitus (NIDDM), who never received antidiabetic medication before, and on a group of 17 healthy adults. The patients were administered treatment with metformin, 1,000 mg/day. Plasmatic and urinary concentration of magnesium have been measured, copper and zinc along with the concentrations of glucose, HDL, LDL, cholesterol, tryglicerides, HbA1c, and total erythrocyte magnesium, in advance and after 3 months of treatment. Data showed significant differences in the NIDDM group vs the control group: for plasma magnesium—1.95 ± 0.19 vs 2.20 ± 0.18 mg/dl, p < 0.001; urine magnesium—237.28 ± 34.51 vs 126.25 ± 38.22 mg/24 h, p < 0.001; erythrocyte magnesium—5.09 ± 0.63 vs 6.38 ± 0.75 mg/dl, p < 0.001; plasma zinc—67.56 ± 6.21 vs 98.41 ± 20.47 μg/dl, p < 0.001; urine zinc—1,347.54 ± 158.24 vs 851.65 ± 209.75 μg/24 h, p < 0.001; plasma copper—111.91 ± 20.98 vs 96.33 ± 8.56 μg/dl, p < 0.001; and urine copper—51.70 ± 23.79 vs 36.00 ± 11.70 μg/24 h, p < 0.05. Treatment with metformin for 3 months modified significant erythrocyte magnesium—5.75 ± 0.61 vs 5.09 ± 0.63 mg/dl, p < 0.001 and urine magnesium—198.27 ± 27.07 vs 237.28 ± 34.51 mg/24 h, p < 0.001, whereas it did not modify significant the plasmatic and urinary concentration of the other cations. The erythrocyte magnesium concentration was inversely correlated with HbA1c (r = −0.438, p = 0.015). The plasma level of copper was positively correlated with HbA1c (r = 0.517, p < 0.003), tryglicerides (r = 0.534, p < 0.003), and cholesterol (r = 0.440, p < 0.05), and the plasma level of zinc was inversely correlated with glycemia (r = −0.399, p = 0.029). Our data show a significant action of metformin therapy, by increasing the total intraerythrocyte magnesium concentration and decreasing the urinary magnesium elimination, positively correlated with the decrease of glycemia and HbA1c in NIDDM patients.     

Precedent Fluctuation of Serum hs-CRP to Albumin Ratios and Mortality Risk of Clinically Stable Hemodialysis Patients

Background

A high sensitivity C-reactive protein to albumin ratio (hs-CRP/Alb) predicts mortality risk in patients with acute kidney injury. However, it varies dynamically. This study was conducted to evaluate whether a variation of this marker was associated with long-term outcome in clinically stable hemodialysis (HD) patients.

Methods

hs-CRP/Alb was checked bimonthly in 284 clinically stable HD outpatients throughout all of 2008. Based on the “slope” of trend equation derived from 5–6 hs-CRP/alb ratios for each patient, the total number of patients was divided into quartiles—Group 1: β≦ −0.13, n = 71; group 2: β>-0.13≦0.003; n = 71, group 3: β>0.003≦0.20; and group 4: β>0.20, n = 71. The observation period was from January 1, 2009 to August 31, 2012.

Results

Group 1+4 showed a worse long-term survival (p = 0.04) and a longer 5-year hospitalization stay than Group 2+3 (38.7±44.4 vs. 16.7±22.4 days, p<0.001). Group 1+4 were associated with older age (OR = 1.03, 95% CI = 1.01–1.05) and a high prevalence of congestive heart failure (OR = 2.02, 95% CI = 1.00–4.11). Standard deviation (SD) of hs-CRP/Alb was associated with male sex (β = 0.17, p = 0.003), higher Davies co-morbidity score (β = 0.16, p = 0.03), and baseline hs-CRP (β = 0.39, p<0.001). Patients with lower baseline and stable trend of hs-CRP/Alb had a better prognosis. By multivariate Cox proportional methods, SD of hs-CRP/alb (HR: 1.05, 95% CI: 1.01–1.08) rather than baseline hs-CRP/Alb was an independent predictive factor for long-term mortality after adjusting for sex and HD vintage.

Conclusion

Clinically stable HD patients with a fluctuating variation of hs-CRP/Alb are characterized by old age, and more co-morbidity, and they tend to have longer subsequent hospitalization stay and higher mortality risk.     

2 型糖尿病合并高血压患者发生心房颤动的相关因素分析

目的:探讨2型糖尿病合并高血压住院患者发生心房颤动的相关因素。方法:选取我院收治的2型糖尿病合并高血压发生心房颤动的患者112例为研究对象(房颤组,n=112例),同期选取与房颤组年龄及性别相匹配的未发生房颤的2型糖尿病合并高血压患者150例为对照组(n=150例),比较两组患者的一般临床资料、实验室检查指标等的差异,用Logistic回归方程分析患者并发房颤的相关因素。结果:与对照组比较,房颤组患者收缩压(SBP)较高,高血压比例高、服用ACEI/ARB类药物偏低(P0.05)、左室射血分数(LVEF)偏低(P0.05)、左房内径(LAD)长(P0.05)、甘油三酯(TC)、低密度脂蛋白胆固醇(LDL-C)、糖化血红蛋白(HbA1c)、血肌酐(Scr)、B型脑钠肽(BNP)、高敏C反应蛋白(hs-CRP)、尿酸均较高(P0.05);多因素Logistic回归方程分析提示:LAD、HbA1c、BNP、hs-CRP、尿酸是患者并发房颤的独立危险因素(P0.05),而服用ACEI/ARB类药物为保护性因素。结论:LAD、HbA1c、BNP、hs-CRP、尿酸均可能是2型糖尿病合并高血压患者发生心房颤动的独立危险因素。     

2 型糖尿病患者肾小管功能测定及其相关因素分析

目的:探讨2型糖尿病(DM)患者的肾小管功能改变,分析其相关因素。方法:将64例2型DM患者根据尿微量白蛋白量分为3组:正常蛋白尿组(<30mg/24h)21例、微量白蛋白尿组(30~300mg/24h)20例和临床蛋白尿组(>300mg/24h)23例,测定各组尿β2微球蛋白(U-β2MG)和尿渗透压(U-OSM)。探讨年龄、DM病程、24h尿白蛋白量、糖化血红蛋白、血压、血脂水平与肾小管功能损害的关系。结果:2型DM患者均有不同程度的尿β2MG增高及尿渗透压减低,在正常蛋白尿组即有4例尿β2-MG和7例尿OSM存在异常;方差分析显示,随尿白蛋白量的增高,尿β2MG逐步增高,尿渗透压逐步减低,三组间差异有统计学意义(F=26.123和13.889,P均<0.01),任两组比较差异均有统计学意义(P均<0.05)。线性回归显示,尿β2MG及尿OSM改变与DM病程、尿白蛋白(U-ALB)、收缩压(SBP)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、低密度脂蛋白(LDL-C)独立有关。结论:2型DM肾脏损害并非仅累及肾小球,在尿微量白蛋白出现之前即可出现肾小管功能异常。联合检测24h尿白蛋白量、尿β2-MG、尿OSM有助于全面评估2型糖尿病患者的肾脏损害情况。严格控制血糖,尽早纠正代谢紊乱对肾小管功能有保护作用。     

2型糖尿病患者肾小管功能测定及其相关因素分析

目的：探讨2型糖尿病（DM）患者的肾小管功能改变,分析其相关因素。方法：将64例2型DM患者根据尿微量白蛋白量分为3组：正常蛋白尿组（〈30mg/24h）21例、微量白蛋白尿组（30~300mg/24h）20例和临床蛋白尿组（〉300mg/24h）23例,测定各组尿β2微球蛋白（U-β2MG）和尿渗透压（U-OSM）。探讨年龄、DM病程、24h尿白蛋白量、糖化血红蛋白、血压、血脂水平与肾小管功能损害的关系。结果：2型DM患者均有不同程度的尿β2MG增高及尿渗透压减低,在正常蛋白尿组即有4例尿β2-MG和7例尿OSM存在异常;方差分析显示,随尿白蛋白量的增高,尿β2MG逐步增高,尿渗透压逐步减低,三组间差异有统计学意义（F=26.123和13.889,P均〈0.01）,任两组比较差异均有统计学意义（P均〈0.05）。线性回归显示,尿β2MG及尿OSM改变与DM病程、尿白蛋白（U-ALB）、收缩压（SBP）、糖化血红蛋白（HbA1c）、总胆固醇（TC）、低密度脂蛋白（LDL-C）独立有关。结论：2型DM肾脏损害并非仅累及肾小球,在尿微量白蛋白出现之前即可出现肾小管功能异常。联合检测24h尿白蛋白量、尿β2-MG、尿OSM有助于全面评估2型糖尿病患者的肾脏损害情况。严格控制血糖,尽早纠正代谢紊乱对肾小管功能有保护作用。     

De-Intensification of Diabetes Treatment in Elderly Patients with Type 2 Diabetes Mellitus

Objective: De-intensification of diabetes treatment is recommended in elderly patients with tight glycemic control at high risk of hypoglycemia. However, rates of de-intensification in endocrine practice are unknown. We conducted a retrospective study to evaluate the rate of de-intensification of antidiabetic treatment in elderly patients with type 2 diabetes mellitus (T2DM) and tight glycemic control.Methods: All patients with ≥2 clinic visits over a 1-year period at a major academic diabetes center were included. De-intensification of diabetes treatment was defined as a decrease or discontinuation of any antidiabetic drug without adding another drug, or a reduction in the total daily dose of insulin or a sulfonylurea drug with or without adding a drug without risk of hypoglycemia.Results: Out of 3,186 unique patients, 492 were ≥65 years old with T2DM and hemoglobin A1c (HbA1c) <7.5% (<58 mmol/mol). We found 308 patients treated with a sulfonylurea drug or insulin, 102 of whom had hypoglycemia as per physician note. Among these 102 patients, 38 (37%) were advised to de-intensify therapy. In a subgroup analysis of patients ≥75 years old with HbA1c <7% (<53 mmol/mol), we found that out of 23 patients treated with a sulfonylurea drug or insulin and reporting hypoglycemia, 11 (43%) were advised de-intensification of therapy. There were no significant predictors of de-intensification of treatment.Conclusion: Our study suggests that de-intensification of antidiabetic medications is uncommon in elderly patients with T2DM. Strategies may need to be developed to prevent the potential harm of overtreatment in this population.Abbreviations: ADA = American Diabetes Association; CGM = continuous glucose monitoring; HbA1c = hemoglobin A1c; T2DM = type 2 diabetes mellitus; UKPDS = United Kingdom Prospective Diabetes Study     

Advances in Lipid Testing and Management in Patients with Diabetes Mellitus

ObjectiveTo review the pathophysiologic basis for the classic phenotype associated with diabetic dyslipidemia, discuss recent advances in lipid and lipoprotein testing for risk assessment and lipid therapy monitoring, and summarize a systematic approach to the clinical management of diabetic dyslipidemia.MethodsWe review the pertinent literature, including treatment guidelines and results of major clinical trials, and discuss the effectiveness of various pharmacologic interventions for management of lipid levels in patients with diabetes.ResultsThe incidence and prevalence of type 2 diabetes mellitus continue to escalate globally at alarming rates. Diabetes predisposes to multiple microvascular and macrovascular complications, including cardiovascular disease, the number 1 cause of mortality in the United States. The third report of the National Cholesterol Education Program Adult Treatment Panel in 2001 identified diabetes as a coronary heart disease (CHD) risk equivalent, in light of the evidence that CHD risk in persons with diabetes is similar to that of nondiabetic persons with established CHD. Diabetic dyslipidemia is characterized by a constellation of lipid derangements—hypertriglyceridemia, a low concentration of high-density lipoprotein cholesterol (HDL-C), and a high concentration of small, dense low-density lipoprotein (LDL) particles—that accelerate the progression of atherosclerotic disease and the development of atherothrombotic events.ConclusionStatin trials have demonstrated significant reductions in morbidity and mortality from cardiovascular diseases, including in patients with diabetes. Nevertheless, many patients who achieve their LDL cholesterol (LDL-C) goal still have residual CHD risk. Diabetic dyslipidemia contributes to this residual risk because of the increased concentration of atherogenic apolipoprotein B-containing lipoproteins that can persist despite normalized LDL-C levels and low HDL-C levels. Recent clinical trials emphasize the importance of intensive lipid lowering to achieve recommended goals for LDL-C, non-HDL-C, and apolipoprotein B. (Endocr Pract. 2009;15:641-652)     

血清脂联素水平对老年维持性血液透析患者心脑血管事件发生风险及预后的影响

目的:探讨老年维持性血液透析(MHD)患者血清脂联素(adiponectin,ADPN)水平与其心脑血管事件发生风险及其预后的关系。方法:采用酶联免疫吸附实验(ELISA)检测76例老年MHD患者血清ADPN水平,以5 mg/L为界,以5 mg/L为低ADPN组,≥5 mg/L为高ADPN组。随访观察两组心脑血管事件的发生情况及预后。采用Cox回归分析血清ADPN水平和心脑血管事件对老年MHD患者的预后影响。结果:76例老年MHD患者的血清ADPN水平为(11.10±10.68)mg/L,其中低ADPN组患者有33例,高ADPN组患者有43例。与低ADPN组相比,高ADPN组患者的心脑血管事件发生率明显下降,而生存时间明显延长(P0.05)。Cox回归分析显示低ADPN水平和发生心脑血管事件是老年MHD患者生存时间的危险因素(P0.05)。结论:血清ADPN水平可作为老年MHD患者心脑血管事件的预测指标,并与患者的预后相关,有较好的临床应用价值。     

Intraleukocytic Bactericidal Activity in Patients Receiving Corticosteroid and Radiation Therapy,and in Patients with Diabetes Mellitus

Bactericidal activities of peripheral white blood cells obtained from patients and from healthy persons were examined in vitro. The results obtained are summarized as follows. 1. Peripheral white blood cells from patients receiving corticosteroid and radiation therapy showed decreased levels of intracellular bactericidal activities against Staphylococcus aureus. The leukocytes from almost all patients examined displayed intense activities of intracellular bacterial killing against Streptococcus pyogenes. 2. Only polymorphonuclear leukocytes (PMNs) and macrophages obtained from patients in severe stages of diabetes mellitus exhibited decreased levels of intracellular bactericidal activities against S. aureus. 3. The leukocytes from all patients examined exhibited the same levels of intracellular bactericidal effects against S. pyogenes as leukocytes from healthy persons. 4. Pseudomonas aeruginosa, which was phagocytized by PMNs obtained from healthy persons, demonstrated a remarkable degree of resistance to any intracellular bactericidal effect.     

Creatine Kinase Elevation,Lactacidemia, and Metabolic Myopathy in Adult Patients with Diabetes Mellitus

ObjectiveTo determine the frequency of elevated creatine kinase (CK) levels among patients with diabetes mellitus and to determine how often elevated CK is attributable to primary myopathy.MethodsIn this prospective study, we investigated how often CK, aspartate aminotransferase, alanine aminotransferase, and resting lactate were elevated among consecutive diabetic patients attending our clinic. Those with elevated CK values were offered a neurologic workup.ResultsNinety-nine patients with diabetes mellitus, aged 19 to 87 years, were assessed between May 2008 and April 2010. Seven patients had type 1 diabetes and 92 patients had type 2 diabetes. CK, aspartate aminotransferase, alanine aminotransferase, and resting lactate were elevated in 19 of 99, 25 of 99, 22 of 99, and 24 of 98 patients, respectively. Eleven of 19 patients with increased CK were self-injecting insulin. Ten of 24 patients with elevated serum lactate took metformin. Seven of 19 patients with elevated CK consented to neurologic workup. Two of the 7 had elevated resting lactate. In all 7 patients, the findings from neurologic investigation were indicative of a metabolic defect and further diagnostic evaluation was recommended.ConclusionsIn diabetic patients attending our clinic, elevated CK levels occur in one-fifth and lactacidemia occurs in one-quarter. Elevated CK levels are attributable to a primary metabolic myopathy in most cases. Elevated CK levels in the setting of diabetes mellitus require further neurologic evaluation. (Endocr Pract. 2012;18:387-393)     

Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance,Adiponectin, and Polycystic Ovary Syndrome History

Background

Fibroblast growth factor 19 (FGF19) and FGF21 are considered to be novel adipokines that improve glucose tolerance and insulin sensitivity. In the current study, we investigated serum FGF19 and FGF21 levels in patients with gestational diabetes mellitus (GDM) and explored their relationships with anthropometric and endocrine parameters.

Method

Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in patients with GDM (n = 30) and healthy pregnant controls (n = 60) matched for maternal and gestational age. Serum FGF19 and FGF21 levels were correlated with anthropometric, metabolic, and endocrine parameters.

Results

Circulating levels of FGF19 were significantly reduced in patients with GDM relative to healthy pregnant subjects, whereas FGF21 levels were increased in GDM patients. Serum FGF19 levels independently and inversely correlated with insulin resistance (increased homeostasis model assessment of insulin resistance, HOMA-IR) and were positively related to serum adiponectin in both groups. In contrast, serum FGF21 levels independently and positively correlated with insulin resistance and serum triglycerides and were inversely related to serum adiponectin. In addition, in the combined population of both groups, those women with preconception polycystic ovary syndrome (PCOS) history had the lowest levels of FGF19, which were significantly lower than those in GDM patients without PCOS history and those in controls without PCOS history.

Conclusions

Circulating FGF19 levels are reduced in GDM patients, in contrast with FGF21 levels. Both serum FGF19 and FGF21 levels are strongly related to insulin resistance and serum levels of adiponectin. Considering the different situation between FGF19 and FGF21, we suggest that reduced serum FGF19 levels could be involved in the pathophysiology of GDM, while increased serum FGF21 levels could be in a compensatory response to this disease.     

北京市2型糖尿病患者抑郁状况的横断面调查及其危险因素分析

目的:探讨北京市2型糖尿病(T2DM)患者抑郁症发病情况及其危险因素,为T2DM合并抑郁症的防治提供依据。方法:采取横断面调查的方法对2016年1月-2016年12月中国人民解放军总医院健康管理研究院体检中患T2DM的3000例患者随机抽取1200例进行调查,所有患者进行Zung抑郁自评量表(SDS)测评,根据SDS结果分为T2DM合并抑郁症组和T2DM非抑郁症组。应用单因素和多因素Logistic回归法分析T2DM合并抑郁症的危险因素。结果:北京市T2DM患者抑郁症患病率为21.93%,不同性别T2DM患者抑郁症患病率比较无统计学差异(P0.05)。单因素分析显示,北京市T2DM患者抑郁症发病与糖尿病病程、运动情况、胰岛素治疗、并发症情况、糖化血红蛋白有关(P0.05),与饮食控制、血糖监测情况、收缩压、舒张压、胆固醇、甘油三酯无关(P0.05)。多因素Logistic回归分析显示糖尿病病程≥10年、胰岛素治疗、并发症≥3个、糖化血红蛋白≥8.0%是北京市T2DM患者抑郁症发病的危险因素(P0.05),经常运动是北京市T2DM患者抑郁症发病的保护性因素(P0.05)。结论:北京市T2DM患者抑郁症患病率为21.93%,糖尿病病程≥10年、胰岛素治疗、并发症≥3个、糖化血红蛋白≥8.0%是北京市T2DM患者抑郁症发病的危险因素,经常运动是北京市T2DM患者抑郁症发病的保护性因素。     

血清胆红素、YKL-40、HMGB-1对糖尿病合并冠心病患者的临床意义

目的:探讨血清胆红素、人类软骨糖蛋白-39(YKL-40)、高迁移率族蛋白1(HMGB-1)对糖尿病合并冠心病患者的临床意义方法:选择2017年1月至2018年12月我院接诊的190例2型糖尿病患者,根据是否合并冠心病分为单纯糖尿病组121例和糖尿病合并冠心病组69例,并选择同期在我院接受体检的100例健康者作为对照组。比较三组临床生化指标、血清胆红素、YKL-40、HMGB-1及不同病变支数、不同病变程度糖尿病合并冠心病组血清胆红素、YKL-40、HMGB-1的表达。结果:三组空腹血糖(FBG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血清胆红素、YKL-40、HMGB-1比较差异均有统计学意义(P0.05);不同病变支数、病变程度糖尿病合并冠心病患者血清胆红素、YKL-40、HMGB-1比较差异均有统计学意义(P0.05);经两两Pearson线性相关性分析结果显示,血清胆红素和Gensini评分呈负相关(r=-0.812,P0.01),YKL-40、HMGB-和Gensini评分正相关(r=0.873、0.801,P0.01)。结论:在糖尿病合并冠心病患者中,血清胆红素的表达明显降低,YKL-40、HMGB-1明显升高,且随着冠脉病变程度的加重变化更明显,本研究也为后期血清胆红素、YKL-40、HMGB-1在该病的早期诊断、预防、治疗效果评价等方面提供了依据     

糖尿病肾病维持性血液透析患者低血糖发生情况及其影响因素的Logistic回归分析

摘要 目的：探讨糖尿病肾病（DN）维持性血液透析患者低血糖发生情况,并分析其影响因素。方法：选择2018年7月~2021年2月期间收治的100例DN维持性血液透析患者,记录低血糖发生情况,按照是否发生低血糖将患者分为低血糖组（n=47）和无低血糖组（n=53）。收集两组患者的临床资料,采用多因素Logistic回归分析DN维持性血液透析患者低血糖发生的影响因素。结果：100例患者1个月内共检测血糖 1200次,其中有47例出现低血糖症状,低血糖发生率为47.00%（47/100）,53例患者未发生低血糖。DN维持性血液透析患者低血糖发生与性别、婚姻状况、工作状况、医保类型、维持性血液透析方式、收缩压、空腹血糖（FBG）、内生肌酐清除率（Ccr）、低密度脂蛋白胆固醇（LDL-C）、三酰甘油（TG）无关（P>0.05）,而与年龄、DN病程、体质量指数、文化程度、尿微量蛋白尿排泄率（UAER）、用药依从性、自我管理能力、照护能力有关（P<0.05）。多因素logistic回归性分析结果显示：年龄偏大、DN病程偏长、体质量指数偏低、UAER偏高是DN维持性血液透析患者低血糖发生的危险因素,而用药依从性、照护能力良好则是DN维持性血液透析患者低血糖发生的保护因素（P<0.05）。结论：DN维持性血液透析患者低血糖发生率较高,其中年龄偏大、DN病程偏长、体质量指数偏低、UAER偏高是DN维持性血液透析患者低血糖发生的危险因素,而用药依从性、照护能力良好则是其保护因素。